Literature DB >> 8083235

High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130.

L D Ward1, G J Howlett, G Discolo, K Yasukawa, A Hammacher, R L Moritz, R J Simpson.   

Abstract

The high affinity human interleukin-6 (IL-6) receptor complex consists of IL-6 and two membrane-associated receptor components, the IL-6 receptor (alpha-subunit) and the high affinity converter and signal transducing molecule, gp-130 (beta-subunit). Recombinant IL-6 and the extracellular ("soluble") components of the IL-6 receptor (sIL-6R) and gp-130 (sgp-130) have been prepared in order to investigate the stoichiometry and binding of these components in the low affinity (IL-6.sIL-6R) and high affinity (IL-6.sIL-6R.sgp-130) IL-6 receptor complexes. Using a combination of size-exclusion chromatography and analytical ultracentrifugation analysis, in the low affinity receptor complex, IL-6 was shown to bind sIL-6R in a stoichiometric ratio of 1:1, whereas the high affinity ternary complex is hexameric consisting of two molecules each of IL-6, sIL-6R, and sgp-130. This is the first direct demonstration of a higher order arrangement for receptor cytokine interactions that exhibit both high and low affinity complexes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083235

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  A rhesus macaque rhadinovirus related to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 encodes a functional homologue of interleukin-6.

Authors:  J A Kaleeba; E P Bergquam; S W Wong
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  Receptor recognition by gp130 cytokines.

Authors:  J Bravo; J K Heath
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.

Authors:  J N Varghese; R L Moritz; M-Z Lou; A Van Donkelaar; H Ji; N Ivancic; K M Branson; N E Hall; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

4.  Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution.

Authors:  J G Zhang; C M Owczarek; L D Ward; G J Howlett; L J Fabri; B A Roberts; N A Nicola
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

5.  The crystal structure of human interferon beta at 2.2-A resolution.

Authors:  M Karpusas; M Nolte; C B Benton; W Meier; W N Lipscomb; S Goelz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

7.  Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.

Authors:  Weirong Wang; Xiaofeng Wang; Rajitha Doddareddy; Damien Fink; Thomas McIntosh; Hugh M Davis; Honghui Zhou
Journal:  AAPS J       Date:  2013-11-28       Impact factor: 4.009

Review 8.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

9.  Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization.

Authors:  G Courtois; L Bénit; Y Mikaeloff; M Pauchard; M Charon; P Varlet; S Gisselbrecht
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha- and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding.

Authors:  F C Stomski; Q Sun; C J Bagley; J Woodcock; G Goodall; R K Andrews; M C Berndt; A F Lopez
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.